Venus Remedies Secures 5 New Global Drug Approvals Across 4 International Markets

Key numbers

Net Profit Growth	139.3%Q1 YoY Growth
Market Cap	₹2,192 CrPharmaceuticals
Revenue TTM	₹811.27 CrTrailing 12 Months
P/E Ratio	18.87Sector PE 45.11

Key highlights

• Authorizations secured for Vancomycin and Fluorouracil in the Kazakhstan market
• Company received marketing approval for oncology drug Fulvestrant in Peru
• Kuwait regulatory authorities granted authorization for Methotrexate injectable
• Approval for antibiotic Meropenem obtained in the Argentina market
• Company footprint now extends to over 100 countries globally

Strengthening Footprint in Critical-Care Injectables

Venus Remedies Limited has achieved five new marketing authorizations across Kazakhstan, Peru, Kuwait, and Argentina, specifically targeting high-potential regions in the CIS, Latin America, and the Middle East. The approvals cover essential treatments including Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate in Kuwait, and Meropenem in Argentina. These milestones are part of the company's long-term strategy to expand its pharmaceutical portfolio in global markets.

As a leader in critical-care injectables, the company now maintains an international presence in more than 100 countries, focusing on providing accessible, quality pharmaceutical solutions to a diverse patient base worldwide.

A Sustained Pipeline of International Approvals

• September 29, 2026: Six authorizations received across Africa and Latin America including Chile and Senegal
• September 1, 2026: Marketing authorization obtained for Gemcitabine in Georgia
• May 22, 2026: Saudi Food and Drug Authority approval for Plerixafor injection
• May 7, 2026: First Argentina approval secured for generic antibiotic Ceftriaxone
• May 4, 2026: Ten new authorizations across Asia, Europe, and Africa including Philippines

Management on Strategic Market Expansion

Our international growth strategy is centred on expanding our reach in high-potential markets while strengthening our product portfolio. We are committed to pursuing new opportunities through regulatory excellence, differentiated offerings and a sustained focus on global market expansion.

Rising Margins and Robust Financial Performance

The global expansion follows a strong financial performance in the first quarter of fiscal year 2026-27. For the quarter ended June 30, 2026, Venus Remedies reported a net profit of ₹22.97 crore, marking a 139.3% increase compared to the previous year. Operating revenue grew by 35.6% year-over-year to ₹178.86 crore, while operating margins improved significantly to 19.1%, up from 7.7% in the same period last year.

With a trailing twelve-month (TTM) P/E ratio of 18.87, the company is trading at a discount to the sector average P/E of 45.11, reflecting steady valuation metrics alongside its recent 255.36% one-year price appreciation.

What to watch next

• Board meeting to approve Q2 FY2026-27 financial results on October 26, 2026
• Completion and commissioning of 'Venusian Chambers' R&D centre by January 2027
• Commercial rollout of the five newly approved pharmaceutical products in their respective markets

“These marketing authorisations mark another step in strengthening our international presence and expanding our product reach across diverse markets. We remain focused on building a strong global portfolio and making quality pharmaceutical solutions accessible to more patients worldwide.”

Venus Remedies · financial snapshot

Share price	₹1640
Market capitalisation	₹2,192.19 Cr
Revenue (annual)	₹769.60 Cr
Net profit (annual)	₹102.79 Cr
Revenue (latest quarter)	₹178.86 Cr-31.05% vs previous quarter
Net profit (latest quarter)	₹22.97 Cr-51.63% vs previous quarter
P/E (TTM)	18.87×Sector 45.11×
Promoter holding	41.76%0.00% QoQ
FII holding	3.14%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.